longitudinal sequencing to monitor brca reversion mutations | tempus case study
Published 3 years ago • 938 plays • Length 3:16Download video MP4
Download video MP3
Similar videos
-
58:17
asco 2023 | the evolving landscape in precision oncology
-
12:21
discover novel targets & applications with tempus explore | tempus webinar
-
18:38
founder stories: eric lefkofsky, founder and ceo of tempus labs
-
6:00
disruptor 50: tempus ceo on ai-driven health-care solutions
-
2:01
generation of comprehensive thoracic oncology database l protocol preview
-
2:21
seabat t-series normalized backscatter
-
4:09
rps alignment by mcosmos
-
![biotector system-c toc analyzer [english]](https://i.ytimg.com/vi/kTDZ31TxWy0/mqdefault.jpg)
6:24
biotector system-c toc analyzer [english]
-
2:18
the importance of multi-gene panel testing for brca mutations
-
2:21
a study of talazoparib in somatic brca1/2 mutant mbc identified by cfdna or tumor tissue genotyping
-
21:19
repeat biopsies & emerging technologies for plasma sampling of mutations
-
43:58
tales from the trenches™ with eric lefkofsky, ceo & founder, tempus
-
2:01
ptr-tof-ms, sampling system & tailored data analysis: bioprocess monitoring l protocol preview
-
2:01
trpv1 purification and reconstitution for spectroscopic analysis | protocol preview
-
18:38
tempus ceo lefkofsky on data-driven medicine
-
10:22
dr. david agus & eric lefkofsky talks about using ai to pivot and combat covid-19 | tempus
-
2:01
silencing: brca2 to identify novel brca2-regulated biological functions l protocol preview
-
3:48
transcutaneous monitoring
-
3:03
sequencing in brca-positive tnbc patients
-
4:01
bio-rad tc20 automated cell counter | msu phm/tox cell culture core
-
2:00
testing patients for brca 1/2 mutation – guiding treatment, and reducing risk: 2022 esmo florida